CGCI: Cancer Genome Characterization Initiative

The Cancer Genome Characterization Initiative (CGCI) uses molecular characterization to uncover distinct features of rare cancers. Current projects perform comprehensive molecular cataloging of HIV+ and other rare adult and pediatric cancers. The research community can use CGCI data to gain insights into the underlying mechanisms of these cancers and identify potential therapeutic targets.

Cancer Genome Characterization Initiative Banner. Links to Program Page

News & Publications

Malignant B-cell lymphocytes seen in Burkitt's lymphoma, stained with hematoxylin and eosin (H&E) stain.
January 07, 2019

Though generally curable with intensive chemotherapy in resource-rich settings, Burkitt lymphoma (BL) remains a deadly disease in older patients and in sub-Saharan Africa. Epstein-Barr virus (EBV) positivity is a feature in over 90% of cases in malaria-endemic regions and up to 30% elsewhere....

Projects

Burkitt Lymphoma

The goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to explore potential genetic changes in patients with Burkitt lymphoma (BL) that could lead to better prevention, detection, and treatment of this rare and aggressive cancer.

HIV-Associated Cancers

The Office of Cancer Genomics (OCG), along with the Office of HIV and AIDS Malignancies (OHAM), initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients.

Medulloblastoma

CGCI developed the Medulloblastoma Project to apply newly emerging genomic methods towards the discovery of novel genetic alterations in medulloblastoma (MB).

Non-Hodgkin Lymphoma

CGCI initiated the Non-Hodgkin Lymphoma Project to elucidate the mutation spectrums of the two most abundant forms of non-Hodgkin lymphoma (NHL)Opens in a New Tab: follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

Last updated: January 03, 2019